Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report

Table 1 Biometric, serum and metabolic data:

	ZL	ZL+S	ZDF	ZDF+E	ZDF+S	ZDF+S+E	ZDF+S+H	P-value
n	9	9	9	8	8	8	7
Body weight at week 14 (g)	325 ± 5	335 ± 7	341 ± 13	345 ± 9	357 ± 10	347 ± 8	360 ± 9	0.11
Body weight at week 24 (g)	381 ± 7	372 ± 8	362 ± 13	365 ± 13	371 ± 18	348 ± 10	369 ± 13	0.60
Serum glucose levels (mg per 100 ml) at week 14	95 ± 7*	96 ± 9*	377 ± 22	363 ± 15	344 ± 19	375 ± 7	389 ± 24	< 0.001
Serum glucose levels (mg per 100 ml) at week 24	91 ± 7*	83 ± 5*	408 ± 21	425 ± 27	319 ± 30♠	367 ± 34	364 ± 20	< 0.001
Mean systolic blood pressure over treatment periode (mmHg)	147 ± 3	150 ± 3	134 ± 3¥	138 ± 3	144 ± 4¥¥	139 ± 4	140 ± 3	< 0.001

Abbreviations: ZL: Zucker lean on normal diet. ZL + S: Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + E: Zucker diabetic fatty on eplerenone therapy. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E: Zucker diabetic fatty on high salt diet with eplerenone therapy. ZDF + S + H: Zucker diabetic fatty on high salt diet with hydralazine therapy.
Post hoc testing: * P < 0.001 ZL and ZL + S vs. all other groups. ¥ P < 0.001 ZDF vs. ZL. ¥¥ P < 0.01 ZDF + S vs. ZDF. ♠ P < 0.05 ZDF + S vs. ZDF.

ISSN: 1475-2840